VICORE PHARMA HOLDING AB - Vicore continues to strengthen its leadership in idiopathic pulmonary fibrosis (IPF) drug development by appointing
Dr. Lindmark as its new Chief Medical Officer Dr. Lindmark brings deep expertise in late-stage clinical development for respiratory diseases, having developed Symbicort and several other global respiratory brands- Appointment reflects Vicore’s advancement to late-stage development in IPF, following the interim phase 2a AIR data read-out showing potential for improving lung function
A luminary in advancing respiratory medicines,
Rohit Batta, outgoing Chief Medical Officer, has accepted a Managing Director role leading a Swiss biopharmaceutical venture company. As he transitions from his position, Vicore reinforces its commitment to develop life-changing treatments for patients suffering from lung diseases such as IPF through this appointment.
“We are so pleased to welcome Bertil to Vicore,” said
“I am very excited to join Vicore at this transformational stage. The recently presented AIR data suggest that improving lung function in IPF is possible, an absolute holy grail in this truly devastating disease,” said
For further information, please contact:
This information was submitted for publication on
About
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European orphan drug designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
© Modular Finance, source
